Indication
Irritable Bowel Syndrome with Diarrhea
9 clinical trials
13 products
1 drug
Product
CIN-103Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Status: Recruiting, Estimated PCD: 2025-02-09
Product
PlaceboClinical trial
Direct Measurement of Gastrointestinal Permeability Change in Response to Aquamin®Status: Recruiting, Estimated PCD: 2024-08-01
Product
AquaminClinical trial
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Live SK08 Powder (Bacteroidetes Fragilis) in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)Status: Recruiting, Estimated PCD: 2026-04-01
Product
Live SK08Clinical trial
The Role of Breath Testing in Enriching the Likelihood of Response to Rifaximin in Patients With Diarrhea IBSStatus: Recruiting, Estimated PCD: 2025-01-01
Product
RifaximinClinical trial
A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)Status: Completed, Estimated PCD: 2022-11-08
Product
AldaferminDrug
VarlilumabClinical trial
To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With DiarrheaStatus: Completed, Estimated PCD: 2023-03-27
Product
MebeverineProduct
Psyllium HuskProduct
Amitriptyline HydrochlorideClinical trial
A Randomized Single-Blind Controlled Trial Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without ConstipationStatus: Recruiting, Estimated PCD: 2024-07-01
Product
NitazoxanideClinical trial
Evaluation of the Effectiveness and Safety of Lactobacillus Fermentum and Lactobacillus Delbrueckii (Lactobacillus LB) in the Treatment of Patients With Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D)Status: Completed, Estimated PCD: 2023-01-29
Product
Lactobacillus LBClinical trial
A Phase II, Double-blind, Randomized, Parallel-group, Placebo-controlled Trial to Evaluate the Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With DiarrheaStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Product
DT01Product
DT01-Placebo